Lung Cancer in 2021 and Beyond
Expert perspectives and strategic insights on the latest therapeutic developments and translational research in lung cancer treatment. Topics include clinical decision-making, the extent emerging data will affect ongoing research, development of new compounds, and future treatment paradigms.
FACULTY CHAIR
Corey Langer, MD, FACP
University of Pennsylvania, PA, USA
Faculty Members
Karen Reckamp, MD
Cedars-Sinai Medical Center, Los Angeles, CA, USA
Edward Garon, MD, MS
University of California, Los Angeles, CA, USA
Nasser Hanna, MD
Indiana University Simon Cancer Center, Indianapolis, IN, USA
Antoinette Wozniak, MD, FACP, FASCO
UPMC Hillman Cancer Center, Pittsburgh, PA, USA
Ignacio I. Wistuba, MD
MD Anderson Cancer Center, Houston, TX, USA
Roy Herbst, MD, PhD
Yale Cancer Center, New Haven, CT, USA
Natasha Leighl, MD, FASCO
University of Toronto, Ontario, Canada
David Spigel, MD
Sarah Cannon Research Institute, Nashville, TN, USA
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
The report was based on the following topics
- Prognostic and Predictive Biomarkers in NSCLC – Clinical vs Research Relevance (excluding EGFR/ALK)
- New Directions for EGFR-Mutant NSCLC
- Emergence of Immunotherapy and Bispecifics in SCLC
- Therapeutic Landscape for Fusion-Positive NSCLC (ALK, ROS1, NTRK, RET)
- Inhibiting Oncogenic Mutations: Overcoming Mutant KRAS, HER2, MET, and BRAF
- New Directions for Second-Line Therapy
- Perioperative Immunotherapy in Early NSCLC
- Immunotherapy in Unresectable Stage III NSCLC
- First-Line Immunotherapy in Metastatic NSCLC – Single Agent or Combination?
- Biomarkers for Immunotherapy – Making Sense of the Chaos
- EGFR (Less Common Mutations, Including Exon 20 Insertions)
- Promising New Targets/Agents in Lung Cancer
